Patents by Inventor Stuart Bunting

Stuart Bunting has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of C-type natriuretic peptide variants to treat skeletal dysplasia
    Patent number: 11911446
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: February 27, 2024
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Adeno-Associated Virus Factor VIII Vectors, Associated Viral Particles and Therapeutic Formulations Comprising the Same
    Publication number: 20240058423
    Abstract: The invention provides adeno-associated virus (AAV) Factor VIII (FVIII)-encoding/expressing vectors and virus, including AAV FVIII vectors with high expression activity and AAV FVIII vectors that express full-length or truncated functional FVIII protein. The invention also relates to methods of making the herein described AAV FVIII vectors, recombinant AAV FVIII virus particles comprising or expressing such vectors, associated pharmaceutical formulations comprising the same and therapeutic uses thereof.
    Type: Application
    Filed: May 26, 2023
    Publication date: February 22, 2024
    Inventors: Stuart Bunting, Peter Cameron Colosi, Erno Pungor
  • Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
    Publication number: 20230293637
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Application
    Filed: January 20, 2023
    Publication date: September 21, 2023
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic formulations comprising the same
    Patent number: 11690898
    Abstract: The invention provides adeno-associated virus (AAV) Factor VIII (FVIII)-encoding/expressing vectors and virus, including AAV FVIII vectors with high expression activity and AAV FVIII vectors that express full-length or truncated functional FVIII protein. The invention also relates to methods of making the herein described AAV FVIII vectors, recombinant AAV FVIII virus particles comprising or expressing such vectors, associated pharmaceutical formulations comprising the same and therapeutic uses thereof.
    Type: Grant
    Filed: November 6, 2019
    Date of Patent: July 4, 2023
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Stuart Bunting, Peter Cameron Colosi, Erno Pungor
  • Use of C-type natriuretic peptide variants to treat skeletal dysplasia
    Patent number: 11590204
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Grant
    Filed: April 1, 2020
    Date of Patent: February 28, 2023
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
    Publication number: 20200246434
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Application
    Filed: April 1, 2020
    Publication date: August 6, 2020
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Use of C-Type Natriuretic Peptide Variants to Treat Skeletal Dysplasia
    Publication number: 20200246433
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Application
    Filed: April 1, 2020
    Publication date: August 6, 2020
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Use of C-type natriuretic peptide variants to treat skeletal dysplasia
    Patent number: 10646550
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: May 12, 2020
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • STABLE EXPRESSION OF AAV VECTORS IN JUVENILE SUBJECTS
    Publication number: 20200069819
    Abstract: The invention relates to the use of adeno-associated virus (AAV) vectors to achieve long term expression of a transgene in the liver of a juvenile subject. The invention includes the stable long-term amelioration of disease symptoms of the subjection following a single administration of an AAV vector to a juvenile subject, wherein the AAV vector delivers the transgene to the subject's liver.
    Type: Application
    Filed: May 14, 2019
    Publication date: March 5, 2020
    Inventor: Stuart Bunting
  • ADENO-ASSOCIATED VIRUS FACTOR VIII VECTORS, ASSOCIATED VIRAL PARTICLES AND THERAPEUTIC FORMULATIONS COMPRISING THE SAME
    Publication number: 20200061161
    Abstract: The invention provides adeno-associated virus (AAV) Factor VIII (FVIII)-encoding/expressing vectors and virus, including AAV FVIII vectors with high expression activity and AAV FVIII vectors that express full-length or truncated functional FVIII protein. The invention also relates to methods of making the herein described AAV FVIII vectors, recombinant AAV FVIII virus particles comprising or expressing such vectors, associated pharmaceutical formulations comprising the same and therapeutic uses thereof.
    Type: Application
    Filed: November 6, 2019
    Publication date: February 27, 2020
    Inventors: Stuart Bunting, Peter Cameron Colosi, Erno Pungor
  • Adeno-associated virus factor VIII vectors, associated viral particles and therapeutic formulations comprising the same
    Patent number: 10512675
    Abstract: The invention provides adeno-associated virus (AAV) Factor VIII (FVIII)-encoding/expressing vectors and virus, including AAV FVIII vectors with high expression activity and AAV FVIII vectors that express full-length or truncated functional FVIII protein. The invention also relates to methods of making the herein described AAV FVIII vectors, recombinant AAV FVIII virus particles comprising or expressing such vectors, associated pharmaceutical formulations comprising the same and therapeutic uses thereof.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: December 24, 2019
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Stuart Bunting, Peter Cameron Colosi, Erno Pungor
  • USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT SKELETAL DYSPLASIA
    Publication number: 20180207239
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Application
    Filed: January 25, 2018
    Publication date: July 26, 2018
    Applicant: BIOMARIN PHARMACEUTICAL INC.
    Inventors: SHERRY BULLENS, STUART BUNTING, TIANWEI CHOU, AUGUSTUS O. OKHAMAFE, CHRISTOPHER P. PRICE, DANIEL J. WENDT, CLARENCE YAP
  • Use of C-type natriuretic peptide variants to treat skeletal dysplasia
    Patent number: 9907834
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Grant
    Filed: August 1, 2016
    Date of Patent: March 6, 2018
    Assignee: BioMarin Pharmaceutical Inc.
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Adeno-Associated Virus Factor VIII Vectors, Associated Viral Particles and Therapeutic Formulations Comprising the Same
    Publication number: 20170087219
    Abstract: The invention provides adeno-associated virus (AAV) Factor VIII (FVIII)-encoding/expressing vectors and virus, including AAV FVIII vectors with high expression activity and AAV FVIII vectors that express full-length or truncated functional FVIII protein. The invention also relates to methods of making the herein described AAV FVIII vectors, recombinant AAV FVIII virus particles comprising or expressing such vectors, associated pharmaceutical formulations comprising the same and therapeutic uses thereof.
    Type: Application
    Filed: September 23, 2016
    Publication date: March 30, 2017
    Inventors: Stuart Bunting, Peter Cameron Colosi, Erno Pungor
  • USE OF C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT SKELETAL DYSPLASIA
    Publication number: 20170028023
    Abstract: The present disclosure provides for use of variants of C-type natriuretic peptide (CNP), and novel pharmaceutical compositions and formulations comprising CNP variant peptides for the treatment of skeletal dysplasias, one or more symptoms of skeletal dysplasias, such as long bone growth or growth velocity, and other disorders having a skeletal dysplasia and/or CNP-associated symptom or component.
    Type: Application
    Filed: August 1, 2016
    Publication date: February 2, 2017
    Inventors: Sherry Bullens, Stuart Bunting, Tianwei Chou, Augustus O. Okhamafe, Christopher P. Price, Daniel J. Wendt, Clarence Yap
  • Methods of using angiopoietin-like 4 protein to stimulate proliferation of pre-adipocytes
    Patent number: 8633155
    Abstract: ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to modulate cell proliferation, cell adhesion, and cell migration.
    Type: Grant
    Filed: October 5, 2009
    Date of Patent: January 21, 2014
    Assignee: Genentech, Inc.
    Inventors: Hanspeter Gerber, Stuart Bunting, Xiao Huan Liang
  • METHODS OF TREATMENT USING ANTI-OXIDIZED LDL ANTIBODIES
    Publication number: 20110256134
    Abstract: The present invention relates to methods and compositions for increasing insulin sensitivity comprising the administration of anti-oxidized LDL antibodies.
    Type: Application
    Filed: August 27, 2010
    Publication date: October 20, 2011
    Inventors: Stuart Bunting, Sherron Bullens, Roland Carlsson, Anne-Christine Carlsson, Björn Frendéus, Steven Glazer, Kevin Grove, Nick Van Bruggen
  • COMPOSITIONS AND METHODS OF USING ANGIOPOIETIN-LIKE 4 PROTEIN
    Publication number: 20100172915
    Abstract: ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to modulate cell proliferation, cell adhesion, and cell migration.
    Type: Application
    Filed: October 5, 2009
    Publication date: July 8, 2010
    Inventors: Hanspeter Gerber, Stuart Bunting, Xiao Huan Liang
  • Compositions and methods of using angiopoietin-like 4 protein antibody
    Patent number: 7371384
    Abstract: ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to modulate cell proliferation, cell adhesion, and cell migration.
    Type: Grant
    Filed: July 19, 2005
    Date of Patent: May 13, 2008
    Assignee: Genentech, Inc.
    Inventors: Hanspeter Gerber, Stuart Bunting, Xiao Huan Liang
  • Compositions and methods of using angiopoietin-like 4 protein
    Publication number: 20070054856
    Abstract: ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to modulate cell proliferation, cell adhesion, and cell migration.
    Type: Application
    Filed: September 28, 2006
    Publication date: March 8, 2007
    Inventors: Hanspeter Gerber, Stuart Bunting, Xiao Liang